Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1974-7-30
|
pubmed:abstractText |
Clinical pharmacological studies of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288) were conducted in patients with metastatic cancer and leukemia. After administration of 0.5 g intramuscularly, 1 g intramuscularly, and 1 g intravenously, the mean peak concentrations in serum were 18, 35, and 106 mug/ml, respectively. Greater than 80% of ticarcillin was excreted in the urine during the subsequent 6-h period. The mean concentrations in the serum of patients 15 min after they received an intravenous injection of 4 g of ticarcillin with and without probenecid were 508 and 519 mug/ml, respectively. Serum levels were determined in patients who received ticarcillin for therapy of infection in doses of 5 g every 6 h. The mean drug concentration in serum 15 min after the rapid administration of the first dose was 433 mug/ml. Subsequent doses were given during a 2-h infusion and the study was repeated 2 days later. The average initial serum level (4 h after the completion of the preceding dose) was 19 mug/ml, and the mean serum level at 15 min was 213 mug/ml. Drug concentrations in the serum of patients receiving ticarcillin by infusion in doses of 3.5 g every 4 h were also determined. In patients with normal renal function, the average initial serum level (2 h after completion of the preceding dose) was 49 mug/ml and the mean level at 15 min was 210 mug/ml. Drug concentrations in the serum of patients with impaired renal function were considerably higher. No detectable levels of ticarcillin were found in the cerebrospinal fluid.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/4791480-4870276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/4791480-4902581,
http://linkedlifedata.com/resource/pubmed/commentcorrection/4791480-4924999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/4791480-4937796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/4791480-5000263
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0066-4804
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
31-6
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:4791480-Adolescent,
pubmed-meshheading:4791480-Adult,
pubmed-meshheading:4791480-Aged,
pubmed-meshheading:4791480-Carboxylic Acids,
pubmed-meshheading:4791480-Humans,
pubmed-meshheading:4791480-Injections, Intramuscular,
pubmed-meshheading:4791480-Injections, Intravenous,
pubmed-meshheading:4791480-Kidney Diseases,
pubmed-meshheading:4791480-Leukemia,
pubmed-meshheading:4791480-Middle Aged,
pubmed-meshheading:4791480-Neoplasms,
pubmed-meshheading:4791480-Penicillins,
pubmed-meshheading:4791480-Thiophenes,
pubmed-meshheading:4791480-Time Factors
|
pubmed:year |
1973
|
pubmed:articleTitle |
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288).
|
pubmed:publicationType |
Journal Article
|